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Adriana Zingone 1, Sanju Sinha1,2, Michael Ante 3,4, Cu Nguyen5, Dalia Daujotyte3, Elise D. Bowman1,
Neelam Sinha 2, Khadijah A. Mitchell 1, Qingrong Chen5, Chunhua Yan5, Phillipe Loher6,
Daoud Meerzaman5, Eytan Ruppin2 & Bríd M. Ryan 1 ✉

Deciphering the post-transcriptional mechanisms (PTM) regulating gene expression is critical to understand the dynamics underlying transcriptomic regulation in cancer. Alternative
polyadenylation (APA)—regulation of mRNA 3′UTR length by alternating poly(A) site usage
—is a key PTM mechanism whose comprehensive analysis in cancer remains an important
open challenge. Here we use a method and analysis pipeline that sequences 3′end-enriched
RNA directly to overcome the saturation limitation of traditional 5′–3′ based sequencing. We
comprehensively map the APA landscape in lung cancer in a cohort of 98 tumor/noninvolved tissues derived from European American and African American patients. We identify
a global shortening of 3′UTR transcripts in lung cancer, with notable functional implications
on the expression of both coding and noncoding genes. We ﬁnd that APA of non-coding RNA
transcripts (long non-coding RNAs and microRNAs) is a recurrent event in lung cancer and
discover that the selection of alternative polyA sites is a form of non-coding RNA expression
control. Our results indicate that mRNA transcripts from EAs are two times more likely than
AAs to undergo APA in lung cancer. Taken together, our ﬁndings comprehensively map and
identify the important functional role of alternative polyadenylation in determining transcriptomic heterogeneity in lung cancer.
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recision medicine in cancer management often relies on the
use of biomarkers to classify molecular subtypes and stratify
responder and non-responder patients. However,
transcriptomic-based signatures can be confounded by molecular
intratumor heterogeneity, as found in multiple cancer types1–3,
including lung cancer4, which is the leading cause of cancerrelated death in the United States5. Post-transcriptional modiﬁcation (PTM) is a major contributor to transcriptomic heterogeneity. Global regulation of PTM is evident in many immune
cells, including T-cells, where it is involved in cell proliferation,
differentiation, and response to extracellular stress6. Tumor cells
can also rewire the transcriptome via PTM making it important
to understand the dynamics underlying transcriptomic regulation
in cancer cells.
Almost all eukaryotic mRNAs undergo polyadenylation, a
nuclear process that involves the addition of non-templated
adenosines to the 3′ end of transcripts. Approximately 70% of
human genes contain more than one polyadenylation site (polyA
site, PAS). The use of different or alternate PAS is called alternative polyadenylation (APA). APA is a key PTM mechanism
regulating nuclear export, stability, and translational efﬁciency of
mature mRNAs7–10 and leads to multiple forms of the transcript
with different 3′ untranslated region (UTR) lengths10–12. This A/
U rich 3′ UTR is a prominent docking site for RNA regulatory
elements, including miRNAs and RNA binding proteins such as
Hu-Antigen R (HuR), also known as ELAV like RNA binding
protein-1 (ELAV1), through which it regulates transcript stability,
transcript export, and cellular localization and protein
translation13–15. Further, DNA-encoded SNPs located in the
mRNA 3′UTR may not be functional anymore if 3′UTR length is
shortened16.
The selection of a polyA site is a dynamic process that contributes to both normal physiology and pathological
phenotypes10,11,17–20. For instance, during B-cell differentiation,
the use of an intronic PAS generates a secreted form of the IgM
protein while the use of a distal site on the IgM transcript generates a membrane-bound form17. Furthermore, an inherited
mutation that drives the use of a proximal polyA site in the
TNSFRS2 gene—which encodes the cytokine BAFF—leads to
increased BAFF expression and susceptibility to autoimmune
diseases20. Dysregulated APA is also linked with cancer. Sandberg
and Mayr independently demonstrated a relationship between
APA with proliferation and with carcinogenesis11,21, with recent
studies highlighting global shortening of 3′UTR as a characteristic
of the cancer transcriptome11,21.
Although a few studies have assessed APA in lung cancer, they
relied on conventional methods largely based on 5′–3′ RNA-seq
data. This approach can lead to saturation22–24 as the proportion
of ﬁnal reads from a polyA transcript/fragment using either
polyA selected RNA-seq or total RNA-seq can be very low25–27.
This underscores the need to comprehensively and speciﬁcally
map polyA sites and APA in cancer with a method that overcomes this saturation. Since we previously observed that lung
tumors derived from European Americans (EAs) are enriched in
cell proliferation and cell cycle pathways compared with African
American (AAs)28, we designed our study to investigate whether
differences in APA between the two populations exist. Here, using
3′end-enriched RNA and direct mapping of polyA sites, in contrast to traditional 5′–3′ sequencing methods, we identify
dynamic APA events and increase both the depth and accuracy of
the analysis. We ﬁnd that lung cancer cells are signiﬁcantly more
likely to produce mRNA transcripts with shorter 3′UTRs than
normal cells and that these shorter transcripts are related to poor
patient survival. In this study we show that global shortening of 3′
UTR transcripts is present in lung cancer, selection of alternative
polyA sites in both long non-coding and microRNA is a form of
2

non-coding RNA expression regulation, and mRNA transcripts
from EA are two-fold more likely than AA to undergo APA in
lung cancer.
Results
Identiﬁcation, quantiﬁcation, and validation of polyA sites
(PAS). The 3′UTR-seq method generated a nucleotide-level
resolution map of how cells use distinct polyA sites in mRNA
transcripts in lung cancer. We identiﬁed 123,475 PAS, of which
102,005 were annotated to known genes (Ensembl v90). To
validate detected PAS, we compared our data with known polyA
databases where our data mapped to 79% and 86% of the Derti29
and Gruber30 databases, respectively (Fig. 1a), indicating that our
analysis compared well with previously published data and thus
ensuring the quality. We next used External RNA Controls
Consortium (ERCC) spike-in RNAs to evaluate diagnostic performance, limit of detection of ratio estimates, and expression
ratio variability. All aspects of our experiment’s technical performance passed these quality control measures (Supplementary
Fig. 1). Following several detailed ﬁltering steps (see “Methods”
section), 37,037 polyA sites annotated to 17,220 genes remained.
Of those 17,220 genes, 7870 (46%) had more than one polyA site
(Supplementary Data 1) (Fig. 1b), which is lower than the 70%
reported by other studies and is likely due to the stringent ﬁltering approach we applied. Although the majority (79%) of distal
sites were within the 3′UTR as expected, only half of the proximal
polyA sites were, with the rest in introns (35%) or exons (12%)
(Fig. 1c).
Characterization and classiﬁcation of polyA sites in lung cancer. To examine the functional status of polyA sites in lung
cancer, we focused on the 7,870 genes for which we identiﬁed
multiple polyA sites. Of these, 3,531 genes (44%) had statistically
signiﬁcant changes (switches) in polyA site usage between tumor
and adjacent non-involved tissue; 3,119 had enhanced proximal
site usage and 412 had enhanced distal site usage in tumor
relative to adjacent non-involved tissue (Fig. 2a, b and Supplementary Data 2–4). Thus, consistent with other tumor types21,31,
mRNAs are signiﬁcantly more likely to produce transcripts with
shorter 3′UTRs compared with non-transformed cells.
Of the 3,119 transcripts with enhanced use of proximal PAS in
tumor compared with adjacent non-involved tissues, 1,549 were
same-exon, 903 were composite-exon and 667 were skipped-exon
pair types. In contrast, among the 412 genes with signiﬁcantly
increased usage of distal sites, 81 were same-exon, while 233 and
98 were composite-exon and skipped-exon, respectively (Supplementary Data 2 and 3). These results are consistent with previous
studies indicating that a switch in the usage of proximal polyA
sites in cancer involves predominantly same-exon sites31. Many
proximal polyA sites with increased use in tumor tissues were
located in intronic (n = 925) and exonic (n = 301) regions
(Supplementary Data 4) suggesting that use of these sites could
lead to truncated proteins with different amino acid sequences
and/or function. There was no enrichment in sense or anti-sense
transcripts among regulated APA sites (Fig. 2c).
For each gene, we also deﬁned a measure of shortening, the
polyA site index (PSI), which is a ratio of read number from a
proximal site divided by the total number of reads from proximal
and distal sites. The ΔPSI captures the relative use of proximal sites
compared with distal sites in tumor cells compared to non-involved
tissues and conﬁrms that 3′UTR lengths are globally shortened in
lung cancer cells (Supplementary Data 5) (Supplementary Fig. 2a).
Using genome-wide RNA-seq reads from the Quantseq output (see
“Methods” section), we observed that expression of key genes
involved in the regulation of polyadenylation, including CPSF and
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Fig. 1 Identiﬁcation, quantiﬁcation, and validation of poly (A) sites from QuantSeq. a Overlap of polyA sites (y axis) with previously published databases
(Gruber et al.69 [https://www.ncbi.nlm.nih.gov/sra/docs/] SRP065825 and Derti et al. 29 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE30198]) assuring a high quality. Percentages in the legend are reported with spacing −5 to +5 nucleotides around identiﬁed PAS. b Detected
polyadenylation sites across genes: 37,037 poly (A) sites annotated to 17,220 genes, 46% of genes possess more than 1 site (green bars). c Distribution of
proximal and distal site location within the gene.

CSTF, were upregulated in tumors compared with non-involved
lung tissues suggesting a possible mechanism of 3′UTR mRNA
shortening (Fig. 2d).
Although we observed some differences in the speciﬁc
transcripts undergoing 3′UTR shortening in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)
(Supplementary Data 6) (Supplementary Fig. 2b), overall, 3′
UTR length was similar between LUAD and LUSC (Supplementary Fig. 2c).
Molecular and clinical features of lung cancer associated with
APA. To characterize the pathways that are targeted by APA in
lung cancer, we performed a pathway enrichment analysis using
IPA32 and found those mRNA transcripts with shorter 3′UTRs
were enriched with cell cycle/proliferation pathways often dysregulated in cancer, including mTOR and its target ubiquitin
proteolysis pathway, receptor tyrosine kinase signaling and signaling speciﬁc to lung cancer. The mTOR ﬁnding is consistent
with recent evidence identifying activation of the mTOR pathway
as a driver of APA in cancer33. Transcripts with longer 3′UTRs
were generally enriched in metabolism and p53 signaling-related
pathways (Fig. 2e and Supplementary Data 7) collectively suggesting that APA contributes to the molecular features of lung
cancer.
Stress and exposure to various environmental factors can
modulate APA34,35, therefore we asked whether exposure to
tobacco could modulate APA in lung cancer. We compared genes

with regulated polyA sites in tumor tissue only between current
and former smokers but did not detect any signiﬁcant changes
(Supplementary Fig. 3) suggesting that smoking is not a major
driver of APA events in lung cancer.
As cancer cells favor the selection of shorter 3′UTRs, we
reasoned that the trimming of mRNA transcripts could be a
prognostic biomarker. To determine whether APA captures genes
with clinical relevance, we performed a multivariate Cox
regression correcting for patient age, sex, race, and tumor stage
for each gene and identiﬁed a strong prognostic signature based
on the APA usage pattern of 12 genes in lung cancer (Fig. 2f and
Supplementary Data 8), including the type I transmembrane
glycoprotein immunoglobulin CD96 and a key homologous
recombination repair gene POLA2. Further, gene ontology
analysis of APA events associated with survival revealed
enrichment of cellular metabolic processes (Supplementary
Data 9).
Genes with 3′ shortening have a higher concordance between
mRNA and protein levels. When a miRNA engages with its
cognate miRNA binding site, it can induce message degradation or
destabilization. Thus, escape from miRNA repression can result in a
more stable transcript with a longer half-life and relative higher
abundance of the mRNA and resulting in more protein11,21.
Alternatively, mRNA levels are not always affected given that most
miRNA/mRNA binding interactions are imperfect and do not lead
to mRNA degradation. Lastly, the competing-endogenous (ceRNA)
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Fig. 2 Role of alternative polyadenylation in shaping the molecular and clinical features of lung cancer. a Global shortening of 3′UTR detected by
DexSeq2 analysis. The dot plot map shows genes undergoing signiﬁcant 3′UTR shortening (red) or signiﬁcant 3′UTR lengthening (blue) and no changes
(gray) in tumors compared with adjacent non-involved tissues. Each dot corresponds to a gene. b Genomic location of regulated proximal and distal sites in
tumors. c Breakdown of regulated sites by sense/anti-sense strands. d Expression of polyadenylation-related genes in tumor and adjacent non-involved
tissues. Heatmap of combined z-score and gene expression analysis of 29 known polyadenylation factors in tumors compared to non-involved tissues. The
asterisk indicates the degree of signiﬁcance of differentially expressed genes. e Enriched pathways. Pathway signiﬁcantly enriched have a −log10 (p-value)
greater than 1.3 (p-value < 0.05; Fisher’s exact test; one-tailed test). Ingenuity canonical pathways analysis in genes with enhanced proximal and distal
sites. f Relationship between 3′UTR shortening and lung cancer survival. A two-sided log-rank test is used to compare the survival times between two
groups. The p‐value of the log‐rank test statistic is commonly approximated by the chi‐square distribution and thus only approximate in a higher limit.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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hypothesis argues that, rather than affecting mRNA expression in
cis, APA impacts mRNA in trans by altering the stochastic nature
by which the loss of one miRNA binding site frees up miRNAs to
bind to other targets14,19–21,36,37. To test these hypotheses in lung
cancer, we ﬁrst found that among genes with signiﬁcant 3′UTR
shortening, there was an average loss of nine miRNA binding sites
per gene (range 1–51), with enrichment for lung cancer-associated
miR-124, miR-181, let-7, and miR-27 binding sites (Supplementary
Fig. 4a, b and Supplementary Data 10, 11). We calculated a genewise correlation between PSI and expression and found that the PSI
of 1,376 of the 3,531 genes signiﬁcantly correlates with expression
(Supplementary Data 12), roughly evenly split between positive and
negative associations. We then asked, what is the probability of
observing this number of genes (N = 1,376) or greater by chance.
To test this, we shufﬂed the APA matrix 10,000 times and calculated an empirical signiﬁcance (p < 0.17) by counting the number of
times the genes with Spearman Rho > 0.1 are greater than or equal
to 1,376.
To test whether APA could drive a higher concordance
between mRNA-protein levels for genes with shorter 3′UTRs, we
mined cancer cell line encyclopedia (CCLE) proteomics and
RNA-seq data38. Using RNA-seq reads, we inferred the PSI as
before24 and found that genes with higher median PSI (more
shortening) have a stronger correlation between their mRNA and
protein (top 10% vs bottom 10% genes ranked by median PSI,
Wilcoxon rank-sum p = 0.027) (Supplementary Data 13 and
Supplementary Fig. 5). We replicated this observation at a tumor
tissue level using TCGA39 and CPTAC data40,41 where mRNA
levels and protein abundance for the same samples are available
[see “Methods” section] (Wilcoxon rank-sum p = 0.03 [breast]
and p = 0.075 [lung]) (Supplementary Data 13 and Supplementary Fig. 5). These data suggest that the tighter correlation
between mRNA and protein found in both cell lines and tumor
tissues is, at least partially, due to 3′UTR mRNA shortening in
cancer cells.
Identiﬁcation of recurrent cancer-related APA events in noncoding RNAs. Given the evidence that non-coding RNAs also
undergo polyadenylation, we proposed, and subsequently identiﬁed, signiﬁcant APA events in non-coding RNAs. Overall, 955
(12%) of the transcripts with more than one PAS in our analysis
mapped to a non-coding RNA (Supplementary Data 4). Of the 27
miRNA host genes detected by our sequencing method and that
passed the read count threshold, 14 had more than one PAS and,
of these, 10 (71%) underwent signiﬁcant alternative polyadenylation in lung cancer, including miR-155 and let-7B (Supplementary Data 4). Furthermore, our method detected 928 long
non-coding RNAs, of which 231 had more than one polyA site.
Of these, 57 (25%) underwent alternative polyadenylation in lung
cancer, including DLEU1, LINC01138, and PVT1 (Supplementary Data 4).
To test whether APA of non-coding transcripts modulates
expression, we generated corresponding total RNA-seq data and
small RNA-seq data for 39 tumor/non-involved tissue pairs
where we had sufﬁcient tissue and compared the average
difference in tumor and adjacent non-involved PSI to the average
difference in tumor and adjacent non-involved miRNA expression. Of the 10 miRNA host genes that underwent recurrent APA
in lung cancer, two (miR-3936, miR-646) did not have mapped
reads in the small RNA-seq ﬁle. Of the remaining eight, host
miRNA APA was correlated with the expression of the individual
miRNAs residing within the host gene (Fig. 3a and Supplementary Data 14). Interestingly, cancer-related APA can have a bidirectional effect on mature miRNA expression. For example,
decreased use of a proximal polyA site on the miR17HG
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transcript, which includes miR-17, miR-18a, miR-19a, miR-19b,
and miR-92a, is associated with increased mature miRNA
expression in tumors compared with adjacent non-involved
tissues (Fig. 3a). However, in LET7BHG and miR-155, increased
use of a distal polyA site is associated with decreased mature let7b expression in tumors compared with adjacent non-involved
tissue. We also analyzed the impact of APA on isomiR expression
and observed similar trends (Supplementary Data 14). Several of
the long non-coding RNAs that underwent APA in lung cancer,
including DLEU1 and PVT1 which are associated with lung
cancer survival42, also correlated with expression (Fig. 3b and
Supplementary Data 15). We also tested the performance of the
prognostic index separately in EAs and AAs and computed the
hazard ratio (HR) for each population separately (AA HR = 4.1,
p < 0.001; EA HR = 4.3, p < 0.001).
Interestingly, the regions of these non-coding transcripts that
were retained or lost due to APA in cancer cells frequently
overlapped with HuR/ELAV1 binding regions. Further, by
mining RIP-seq data we observed signiﬁcant differential binding
between HuR to the regions retained or lost through APA in both
long non-coding RNAs and microRNAs (Fig. 3c). As HuR
modulates transcripts—through both stabilization43 and
destabilization44, gain or loss of RNA bindings proteins is a
potential mechanism by which APA of non-coding RNAs
controls expression of mature transcripts. For example, increased
use of a distal polyA site on the miR17HG RNA transcript relative
to a proximal one (Supplementary Data 4) leads to the inclusion
of a region with multiple binding sites for HuR proteins in tumor
tissues (Fig. 3a). Indeed, our data show that there is more HuR
binding to this region in cancer, compared with normal cell lines
(Fig. 3c). As the PSI correlates with increased miR-17 cluster
expression, we speculate that this HuR binding leads to greater
transcript stabilization, greater processing, and, therefore, higher
expression.
Collectively, these data suggest that APA of non-coding RNA
transcripts is a recurrent event in lung cancer and that the
selection of alternative polyA sites could be a form of non-coding
RNA expression control.
Population differences 3′UTR length. In a previous transcriptomic analysis of lung cancer in European Americans and
African Americans, we observed that genes dysregulated in
tumors from EAs only are enriched in cell proliferation and cell
cycle pathways compared with AAs28. Given that proliferating
cells are more likely to have shorter 3′UTRs11, we tested the
hypothesis that lung tumors from EAs would be enriched in
regulated gene-level APA events and have global shorter 3′UTRs
compared with AAs. When compared with non-involved adjacent tissues, tumor cells from EAs had more signiﬁcant APA
events compared with AAs (Fig. 4a). Speciﬁcally, of genes with
more than one APA site, 30% of genes (2,276) undergo 3′UTR
shortening in EAs compared with 17% (1,360) in AAs, following
Benjamini-Hochberg FDR-adjusted p-values for each site. This
represents a greater than 2-fold increase of APA events in EAs
(Supplementary Data 16 and 17). We repeated this analysis,
comparing the gene-wise number of APA events (log2PSI value)
in tumor vs non-involved adjacent tissues in both EAs and AAs
using a multivariate regression correcting for patient age, sex,
tumor stage, and smoking status and consistently found a 2-fold
higher number of genes going through APA events in EAs vs
AAs. There was no speciﬁc enrichment in LUSC vs. LUAD
(Supplementary Fig 2d).
As no other large cancer datasets with 3′UTR-speciﬁc sequencing
exist to our knowledge, we mined TCGA 5′–3′ RNA-seq reads from
non-small cell lung cancer24 to test whether EAs have more global
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Fig. 3 Alternative polyadenylation of non-coding RNAs in lung cancer and relationship with expression in microRNAs long non-coding RNAs. a Panels
show the correlation between the average 3′UTR length difference in tumor and adjacent non-involved tissues (PSI) to the average miRNA expression
difference in tumor and adjacent non-involved tissues. In the scatter plot, the y axis denotes the delta PSI and the x axis denotes delta miRNA. b Panels
show the correlation between the average 3′UTR length difference to the average long non-coding RNA expression difference in tumor and adjacent noninvolved tissues. In the scatter plot, the y axis denotes the delta PSI and the x axis denotes delta long-non-coding RNA. c Difference in HuR/ELAV1 binding
to mRNA segments gained and lost through APA based on RNA immunoprecipitation (RIP-seq) assays proﬁle measuring ELAV1/HuR RNA binding of K562
leukemia cells and normal GM12878 cells as a control from GSE35585. For a given gene or element, ELAV1/HuR binding is quantiﬁed by counting the
number of reads between primary proximal and distal polyA site of usage in both cell lines individually. Here in the box plot, the lower and upper hinges of
the boxes correspond to the 25th and 75th percentiles and the whiskers represent the 1.5× inter-quartile range (IQR) extending from the hinges. The center
lines denote the median and the black line represents the rest of the distribution, except for the points that are determined to be “outliers”. A two-tailed
Wilcoxon rank-sum test is used to compute the signiﬁcance of the difference between medians. The p-values are below the minimum ﬂoating integer that
can be computed using standard R and thus the exact value reported by R is 0. Thus, we provide the approximate upper bound reported by R.

3′UTR shortening compared with AAs. We calculated a PSI24 for
each gene and using a similar multivariate regression above, tested
the association between PSI and race correcting for sex, tumor
stage, and age of the patient (this analysis was done in tumors only
as there were not sufﬁcient adjacent non-involved samples from AA
patients for comparison to EAs). We conﬁrmed that while more
genes undergo shortening in EA tumors in comparison to AA
tumors from LUSC (EA = 1,254 compared with AA = 598) and
LUAD (EA = 1,443 compared with AA 1,075) (Supplementary
6

Fig. 6b), the global difference in 3′UTR length, considering tumor
tissue only, is not signiﬁcantly different (Fig. 4c). To test pan-cancer
population differences in APA, we next mined the same data set for
11,265 TCGA samples from 28 cancer types for 7,062 genes45.
Again, we modeled the PSI index as a function of race correcting for
cancer type, sex, tumor stage, and age of the patient. Consistently,
we found a higher number of genes with 3′UTR shortening in EA
tumors compared with AA tumors in pan-cancer (in EA = 1,643
compared to in AA = 1,277) (Fig. 4b). Some of the strongest
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Fig. 4 Race-related differences in global 3′UTR length of genes across multiple cancer types. a Distribution of shortening (red) and lengthening (blue)
events in lung cancer in EAs and AAs. b Pan-cancer population differences shortening (red) and lengthening (blue) events in EAs and AAs. c Comparison
of PSI in EAs and AAs in tumor tissues in TCGA. First, cancer types are categorized by cell type or tissue of origin, if possible, where deﬁned groups are
pan-squamous (squamous cell-derived tumors), pan-adeno (glandular structures in epithelial tissue derived tumors), pan-kidney (tumors originating in the
kidney), and rest (referring to cancer types that cannot be categorized and include LAML, THYM, GBM, LGG, SARC, BRCA, LIHC, OV, TCGT, THCA, and
UCEC; refer here for reference to each cancer type: https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations). Second,
additional categorization was performed based on tissue type (where solid is derived from solid tumors and neural-crest and Hema & Lymph—hematologic
and lymphatic tumors). A two-sided Wilcoxon Rank-sum test has been performed within each cancer type and signiﬁcance before multiple testing
correction is provided. LAML p = 0.55; THYM p = 0.92; GBM p = 0.55; SARC p = 0.15; LUAD p = 0.64; PAAD p = 0.79; PRAD p = 0.42; STAD p = 0.11;
KIRC p = 0.069; KIRP p = 0.756; BLCA p = 0.332; CESC p = 0.816; ESCA p = 0.031; HSNC p = 0.977; LUSC p = 0.703; LUSC p = 0.703; BRCA
p = 0.00011; LIHC p = 0.14103; OV p = 0.14827; TGCT p = 0.65657; THCA p = 0.70424; UCEC p = 0.73852. Here in the box plot, the lower and upper
hinges of the boxes correspond to the 25th and 75th percentiles and the whiskers represent the 1.5× inter-quartile range (IQR) extending from the hinges.
The center lines denote the median and the black line represents the rest of the distribution, except for the points that are determined to be “outliers”. A
two-sided Wilcoxon rank-sum test is used to compute the signiﬁcance of the difference between medians.

differences were observed in breast (p = 0.0001) and esophageal
cancer (p = 0.031), where global shortening of mRNA transcripts
was also observed (Fig. 4c) (Supplementary Data 18).
As demonstrated earlier (Fig. 2d), there is global dysregulation
of proteins involved with APA in cancer, i.e., the PA machinery.
To determine whether the population differences in APA are
related to differential activity of PA machinery between EA and
AA tumors, we computed an PA machinery activity score
(median scaled expression of PA machinery genes and found it to
be positively correlated with PSI-load (Rho = 0.18, p < 2E−16)),
suggesting that expression of machinery-related genes modulates

global APA changes. We then computed the difference in the PA
machinery activity score by race in each cancer type in TCGA and
observed a signiﬁcantly higher activity in BRCA tumors from EAs
compared with AAs (Supplementary Fig. 6c and Supplementary
Data 19), suggesting that population differences in APA could be
driven by population differences in PA-related machinery gene
expression.
We next asked what the underlying genetic basis behind these
PSI differences could be. We ﬁrstly reasoned that if there is a
genetic cause, it is likely to be somatic as we did not observe
signiﬁcant differences in APA in non-involved tissues between
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Fig. 5 Ratio of 3′UTR shortening index (PSI index) in tumors with driver gene mutated vs. wildtype status from TCGA. The ratio of median PSI-load
index (fold change [FC], x axis) between driver gene mutated vs. wildtype tumors (pan-cancer) derived from TCGA for 683 cancer driver genes (COSMIC)
and corresponding p-value of Wilcoxon rank-sum test are shown. The red points are signiﬁcant (FDR < 0.1) past the FC threshold of FC > 0.1 and are
labeled with their HGNC gene names.

EAs and AAs. Testing this hypothesis, we examined the
relationship between somatic mutations in driver genes (682
driver genes census set derived from COSMIC [https://
cancer.sanger.ac.uk/census]) with the 3′UTR shortening index
in TCGA pan-cancer samples (Fig. 5 and Supplementary Data 20).
The top genes whose mutation status are signiﬁcantly associated
(FDR p < 0.1) with the 3′UTR shortening index after FDR
correction are RB1 (FC = 1.1, Wilcoxon rank-sum raw p < 2.6E
−05), ACSL3 (FC = 1.39, Wilcoxon rank-sum p < 0.0001),
ERCC5 (FC = 1.32, Wilcoxon rank-sum p < 0.0002), PD-L1
(FC = 1.31, Wilcoxon rank-sum p < 0.0004), FANCC (FC = 1.17,
Wilcoxon rank-sum p < 0.0004), and NTRK1 (FC = 1.21, Wilcoxon rank-sum p < 0.0006). As the occurrence of these
mutations is not shown to vary by population, we further reason
that somatic mutations are not driving the population differences
in APA that we describe. This observation is also consistent with
Xia et al. 24.
Discussion
Our study uses both a speciﬁc 3′UTR sequencing method that
allows simultaneous genome-wide polyA site identiﬁcation and
an analysis pipeline tailored to detect signiﬁcantly regulated APA
sites in lung cancer. Charting the comparative regulation of polyA
sites in lung cancer, we identify a global shortening of mRNA
transcripts in lung tumor cells relative to non-transformed
adjacent tissue. Almost 50% of genes with more than one polyA
site undergo alternative polyadenylation in lung cancer to produce different transcript isoforms, implying a high degree of
transcriptional heterogeneity at the level of the 3′UTR that is not
usually captured in transcriptomic studies. The global and genespeciﬁc (DICER1, FGF2, TACC1, RAB10, RUNX121, ZEB1,
PDXK, COL1A2, PPP3CB, C6orf89, SAP30L, APH1B, CHURC131)
shortening observed in our study is consistent with previous
ﬁndings in other cancer types using different approaches21,31,46.
8

Pathway analyses suggest that cell proliferation and oncogenic
signaling pathways, including mTOR, are enriched with short
transcript isoforms in lung cancer. Intriguingly, the ubiquitinmediated proteolysis pathway, a major target of mTORC1, is
signiﬁcantly enriched in the same direction. A recent study
demonstrated that the activation of the mTORC1 pathway is a
potential driver of global 3′UTR shortening in cancer33. Long
isoforms are enriched with p53 signaling and metabolic-related
pathways. These patterns are consistent with several previous
observations11,21,40,47–49. Our results suggest that the generation
of shorter 3′UTR transcripts through APA contributes to the
molecular features of lung cancer, as evidenced by the grouping of
genes undergoing APA in lung cancer-related pathways.
The effect of APA on gene expression, not yet fully understood,
is debated and likely multi-modal. One hypothesis is that
expression of a shorter 3′UTR leads to increased mRNA50 or
protein19–21 in cis, a type of gene ampliﬁcation in the absence of
mutations or somatic alterations49. Our data indicate that genes
with short mRNA transcripts have a tighter correlation with their
respective protein products. This observation agrees with the
decrease in concordance between mRNA and protein abundance
in some tissues51,52 and is consistent with studies showing a
stronger gene-wise mRNA/protein correlation in tumor cells than
in normal cells47. Others argue that the selection of short mRNA
3′UTRs through APA is enriched in transcripts predicted to act as
ceRNAs for tumor-suppressor genes14. These associations are
also complicated by the incomplete complementarity between
miRNAs and mRNAs in mammals and the presence of other
RNA stability regions in 3′UTRs, such as ALU elements. The
latter also impacts the stability and expression of a mRNA and
which, equally to miRNAs, can be impacted by 3′UTR
shortening53,54. Further, as our data show, increased use of a
proximal APA site in tumor need not necessarily lie in the 3′UTR
and there are many instances of increased proximal APA use
occurring in an intron or exon. This kind of APA may not impact
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RNA or protein expression per se, but would almost surely
impact the protein type produced. Thus, the ultimate impact of
APA on the transcriptome and proteome is likely dependent on a
multitude of factors.
Given recent evidence linking APA as a cellular stress response
to exogenous stimuli14,35,55, we hypothesized that smoking could
be a potential global regulator of APA in lung cancer. Our data
suggest that while smoking may contribute to the APA of a subset
of genes, it does not appear to be a global regulator. This conclusion is consistent with other studies showing global shortening
of 3′UTRs in cancers not associated with smoking31.
The greater analysis depth of our sequencing method and study
design facilitated the identiﬁcation of APA events. A key ﬁnding
from our study is that non-coding RNAs also undergo recurrent
alternative polyadenylation in lung cancer and that it is a common event. Moreover, it seems to be a mechanism of long noncoding RNA expression, whereby the retention or loss of RNA via
APA modulates binding by HuR, and likely, other RNA binding
proteins as well. While previous work demonstrated that both
long non-coding RNAs and microRNA transcripts undergo
polyadenylation, and that alternative polyadenylation of lncRNA
transcripts was previously described22,46,56–58, our study
demonstrates widespread APA of recurrent and clinically relevant
non-coding RNAs in cancer and may represent a form of transcriptomic regulation for non-coding RNAs in cancer.
We also identiﬁed population differences in APA. On average,
mRNA transcripts from EAs were two times more likely that AAs
to undergo APA in lung cancer compared with non-involved
tissues. However, we did not ﬁnd a globally shorter 3′UTR
landscape in lung cancer in either our own samples or in TCGA.
As population differences in APA had not previously been
addressed to our knowledge, we leveraged the TCGA database
and observed signiﬁcant global shortening of 3′UTRs among EAs
with breast cancer compared with AAs and an inverse trend in
esophageal cancer. We did not observe population differences in
the use of speciﬁc polyadenylation signal hexamers among
regulated PAS (Supplementary Fig. 6a). Previous studies have
shown that most APA events result from the dysregulated
expression of proteins controlling polyadenylation24. We and
others18 observed overexpression of key genes involved in the
regulation of the polyadenylation (PA) machinery, including
CPSF and CSTF, in tumors compared with non-involved lung
tissues and we found a strong correlation between the expression
of 3′end processing machinery genes and shorter 3′UTR length,
consistent with the previous studies18. We, therefore, reasoned
that the differences in APA between EAs and AAs could be due to
global patterns of 3′end machinery expression or focal regulation
by speciﬁc APA factors. In breast cancer, the occurrence of
shorter 3′UTR transcripts was indeed signiﬁcantly linked with a
higher PA machinery score. Interestingly, Tang and colleagues
recently demonstrated a higher concordance between mRNA and
protein in breast tumors from AAs compared with EAs. Our
ﬁndings in breast cancer are consistent with these ﬁndings, where
in general, AAs had a longer 3′UTR compared with EAs, implicating tighter control and regulation of mRNA translation47.
A key strength of this study is our use of a speciﬁc method to
sequence and map polyA sites, rather than traditional 5′–3′
sequencing methods. This method circumvents the issue of
saturation encountered by previous 5′–3′ RNA-seq methods and
enables a comprehensive identiﬁcation of APA events, including,
for example, our identiﬁcation of non-coding RNA isoforms and
recurrent APA in lung cancer. Previous APA studies of cancer
have used EST databases59 and microarrays11,18, which, though
not incorrect, are limited by dependence on the annotation of
APA sites by EST databases, the proportion of genes covered by
the probes, probe design, and technical difﬁculties when a gene
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has more than two polyA sites10. Methods based on traditional
RNA-seq also have limitations. For example, while it is possible to
detect polyA sites through the detection of sequences with
stretches of As, only a small proportion of RNA-seq reads contain
polyA tails, limiting the ability to identify APA events26,27. Of
note, an ultra-deep sequencing study identiﬁed only ~40,000
putative polyA reads (~0.003%) from 1.2 billion total RNA-seq
reads25. Also, short 3′UTRs are often embedded within long ones,
and thus isoforms with short 3′UTRs are commonly overlooked
by transcript assembly tools, though methods have been developed to overcome these limitations24. Thus, by leveraging 3′endenriched RNA-seq methods, we have been able to comprehensively map the APA landscape in lung cancer.
Another strength of our study is the use of predominantly
matched tumor and adjacent non-involved tissues and ERCC
spike-in RNAs as controls for the sequencing method. It is possible that our study has missed some polyA sites—approximately
20% of human polyA sites do not contain a canonical hexamer
(or one of its variants), instead relying on binding to the UGUA
or downstream sequences60. Also, our analysis ﬁltered out polyA
sites without a well-characterized hexamer in the upstream
pipeline making it possible that we overlooked a small portion of
regulated APA events. A limitation of our work regarding
population differences in APA that should be considered is our
use of self-reported race in the classiﬁcation of EAs and AAs. The
race is a socially constructed variable that categorizes people
based on non-biological characteristics.
Some, not all, members of the same race may also share
common biology. We have previously shown that African
American lung cancer patients have greater enrichment of
genomic, transcriptomic, and proteomic proﬁles28,61. However,
these biological determinants cannot account for all the differences observed. While we cannot pinpoint social, environmental,
or genetic factors that would impact population differences in
APA, in line with recent recommendations we have tried
explaining how our populations were selected62.
In summary, our study describes a level of transcriptomic
regulation by APA that is associated with patient survival in lung
cancer and yields insight into tumor biology and transcriptional
heterogeneity that are missed by general transcriptome analyses.
We ﬁnd gene-level population differences in APA in lung cancer,
and both gene-level and global differences in 3′UTR length in
breast cancer. Finally, our description of recurrent and clinically
relevant APA events in non-coding RNAs in lung cancer identiﬁes a form of non-coding RNA expression control whereby
APA acts as a dynamic docking location for RNA binding
proteins.
Methods
Study subjects. Ninety-eight patients with histologically conﬁrmed non-small cell
lung cancer were selected from the National Cancer Institute-Maryland (NCI-MD)
lung cancer study. This NCI-MD Case Control Study was conducted in accordance
with the Declaration of Helsinki. Institutional review board approval was granted
from NCI and participating hospitals and registered on clinicaltrials.gov [https://
clinicaltrials.gov/ct2/show/NCT00339859]. The cohort included 46 AAs and 52
EAs (Table 1). The population accrual and eligibility criteria for this study were
previously described63,64. Written informed consent was obtained from each
participant.
Individuals in this study self-reported as either African American or European
American. Our previous work with this population indicates that the median West
African ancestry in self-reported African Americans is 77%61,65. Eligible
participants took part in a structured in-person interview from which demographic
and lifestyle factors were documented. Clinical data were obtained from medical
records and pathology reports for each patient. Fresh human lung tumor and
matched adjacent non-involved lung tissues were obtained from patients directly
after surgery. Each tissue was transferred to a sample collection tube, ﬂash frozen,
and stored at −80 °C until molecular analyses were performed. The study included
98 tumor tissues and 98 adjacent non-involved tissues (n = 196 total).
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Table 1 Demographic characteristics of the population.

Age
Sex
Male
Female
Smoking status
Never
Former
Current
Missing
Histology
Adenocarcinoma
Squamous
Other
Stage
I
II
III
Missing

African American

European American

p-value

63.7 (8.4)

65.2 (9.3)

0.16

10 (21.7)
36 (78.3)

17 (32.7)
35 (67.3)

3
15
25
3

3
19
29
1

(6.5)
(32.6)
(54.3)
(6.5)

(5.8)
(36.5)
(55.8)
(1.9)

25 (54.3)
14 (30.4)
7 (15.2)

21 (37.5)
21 (37.5)
10 (19.2)

23
14
7
2

35
12
3
2

(50.0)
(30.4)
(15.2)
(4.4)

(67.3)
(23.1)
(5.8)
(3.9)

0.28

0.78

0.57

0.27

RNA library preparation and sequencing. Construction of RNA libraries was
performed using the QuantSeq Rev 3′mRNA-Seq Library Prep Kit for Illumina
(Lexogen, Vienna, Austria) according to the manufacturer’s instructions. Brieﬂy,
500 ng of total RNA was reverse transcribed with an oligo(dT) primer containing
an Illumina-speciﬁc linker sequence, followed by removal of RNA and secondstrand cDNA synthesis with random primers. The resulting double-stranded
cDNA was puriﬁed with magnetic beads. Libraries were ampliﬁed by PCR with
primers containing Illumina adaptors and sample-speciﬁc barcodes and then
puriﬁed with magnetic beads. The High Sensitivity DNA analysis Kit (Agilent,
Santa Clara, CA) was used for library quantiﬁcation.
Libraries were pooled and sequenced on the Illumina Hiseq 2500 with 100 bp
single-end reads. Eight samples were run per lane, including 4 tumors and 4
adjacent non-involved samples derived from 2 AA and 2 EA to limit bias. The
QuantSeq Rev kit includes a customized sequencing primer that anneals to the
linker sequence previously introduced in the oligo(dT) priming step. Reads are
strand-speciﬁc and generated from the 3′untranslated region and last exon in a
3′–5′ direction. The method generates one fragment per transcript, which also
facilitates gene expression analyses. In total, we sequenced 196 samples, which
produced, on average, 20.6 million reads per sample.

Generation of the global polyadenylation atlas. Data analysis was performed
with expressRNA66 (expressRNA.org; https://github.com/grexor/apa), an opensource modular and scalable platform that provides a complete analytical framework incorporating tools for read alignment, genome annotation, and calling of
differentially polyadenylated genes.
The 3′UTR sequence data were processed and mapped to the genome using
STAR, which allows soft clipping from both 5′ and 3′ ends. On average, 74% of the
reads from each sample aligned to the hg38 reference genome. We then considered
the locus of the last nucleotide of each alignment at the 3′ end and clustered the
signal across all samples to obtain a global polyadenylation atlas. Since oligo-dT
priming is known to cause internal-priming events, we only considered loci that
had any of the 18 characterized PAS in the [−30….−10] nt region relative to the
detected cleavage site30. We additionally ﬁltered out genomic positions that had
more than 6 consecutive As or more than 8 sparse As in any 10 nt window in the
regions spanning the detected cleavage site ([−10….10] nt) to ﬁlter out internalpriming events.
Since cleavage is not a nucleotide exact process and tends to occur within a
small window of positions around the dominant cleavage site, we summed the read
counts from cleavage sites up to 5 nt away from each dominant polyA site66. We
also selected a representative cleavage site for each of the PAS signals. To focus on
fully independent cleavage sites with their own PAS and cis-regulatory elements, we
identiﬁed the dominant polyA sites based on read count and ranked them in
descending order, such that all resulting sites were at least 125 nt apart66. Since 3′
UTR isoforms are not always fully annotated, we added 5 kb of the intergenic
region downstream of each gene. If two genes were closer than 10 kb, only the
region up to the middle of the beginning of the downstream gene was added. To
avoid spurious cleavage and polyadenylation events, we only kept polyA sites that
were present across at least 25% of samples66. To avoid poorly used sites, polyA
sites with less than ten read counts in either adjacent non-involved or tumor tissues
were ﬁltered out. We then discarded those polyA sites that had less than 5% of
reads compared with the major polyA site in the same gene66.
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We further classiﬁed regulated polyA sites based on their position in the gene;
(a) same-exon pairs—if both proximal and distal sites are located in the same exon,
(b) composite-exon—if the proximal site is part of a composite-exon, i.e.,
containing an internal 5′ splice and the two sites were generated by alternative use
of that splice site, and (c) skipped-exon sites—if the proximal site is part of an exon
that is fully spliced66.
Correlation between non-coding RNA expression and APA. We ﬁrst performed
quality and adapter trimming by using the cutadapt tool to remove the NEB 5′
(GTTCAGAGTTCTACAGTCCGACGATC) and 3′ (AGATCGGAAGAGCACA
CGTCT) adapters. For isomiRs, we mapped reads to precursors from miRbase
version 22 using exhaustive string comparisons while disallowing mismatches,
insertions, or deletions. IsomiRs were then annotated to include offset positions67
to indicate how their 5′ and 3′ ends differ from that of the annotated reference
mature.
We used available microRNA binding site annotation from APADB to enrich
the polyA sites. Bedtools set operation were used to assess the lost microRNA
binding sites. Correlation was carried out by using the log2 tumor and normal PSI
ratio and gene transcripts per million (TPM) from RSEM for 60 LincRNA matched
genes. For LincRNA isoforms, the identiﬁcation and quantiﬁcation of APA events
between tumor and matched normal tissues was performed by using delta
Percentage of Distal polyA site Usage Index (dPDUI or ΔPDUI) from DaPARS24
with all default parameters. The same trend was deﬁned as that shorten 3′ APA
corresponds with lower gene expression and genes on opposite trend as that
shorten 3′ APA corresponds with higher gene expression in tumor and normal
samples.
Derivation of PSI from TCGA samples. The ΔPDUI measure derived from
DaPARS24 were mined from The Cancer 3′ UTR Atlas (TC3A), a comprehensive
resource of APA usage for 10,537 tumors across 32 cancer types http://tc3a.org and
converted to PSI (1- PDUI). Codes generated to analyze this data set are provided
at https://github.com/ruppinlab/apa_lung.git. Race information is self-reported.
CTPAC analysis: We downloaded the protein abundance information for
primary breast cancer samples of the TCGA cohort from CTPAC portal [https://
cptac-data-portal.georgetown.edu/datasets] and downloaded their respective
mRNA expression proﬁle from GDAC [https://portal.gdc.cancer.gov/] ﬁrehose
portal. We next ranked each gene by its median PSI index higher to lower and
asked whether the top 10% genes going (high 3′ shortening in tumors) have a
stronger correlation between their mRNA and protein across patients than the
bottom 10% of the genes (high 3′ elongation in tumors). We repeated this analysis
for lung tumors samples by mining the mRNA-protein correlation information
from Gillette et al.41. Codes used to analyze this data set are provided at https://
github.com/ruppinlab/apa_lung.git. Race information is self-reported.
Analysis of RIP-seq data. We downloaded the RNA immunoprecipitation (RIPseq) assays proﬁle measuring ELAV1 DNA binding of transformed K562 leukemia
cells and normal Gm12878 cells as a control from GSE35585 For a given gene or
element (miRNA or long non-coding RNA), ELAV1 binding is quantiﬁed by
counting the number of reads between primary proximal and distal polyA site of
usage in both cell lines individually. Codes used to analyze this data set are provided at https://github.com/ruppinlab/apa_lung.git. Race information for this data
set is self-reported.
Calculation of Polyadenylation Machinery Index. We mined the expression
levels of 19,001 genes in 8749 tumor samples from TCGA cohort68. For a subset of
core regulatory genes of polyadenylation of mRNA pathway (biocarta_cpsf_pathway, M22041, [https://data.broadinstitute.org/gsea-msigdb/msigdb/biocarta/
human/h_cpsfPathway.gif]), we identiﬁed their median z-score expression for each
sample and deﬁned it as PA machinery activity index. Codes used to analyze this
data set are provided at https://github.com/ruppinlab/apa_lung.git. Race is selfreported for this data set.
Identiﬁcation of clinically relevant APA events. To determine whether APA
captures genes with clinical relevance, we ﬁrst performed a lasso regression (feature
selection step) for each gene, which yielded 21 genes whose PSI values are associated independently with survival. Using the PSI levels of these 21 genes and their
corresponding hazard ratio from multivariate regression correcting for patient age,
sex, race, and tumor stage as their linear weights, we generated a prognostic index
for each sample in leave-one-out cross-validation. Thus, the Prognosis Index (PI)
of kth sample is deﬁned as,
m

PI ¼ ∑ βiχi
i¼1

where, β is the cox-risk coefﬁcient of gene i, χ is the gene i PSI value. The patients
with a PI greater than the median are categorized as low-risk and the rest as highrisk (Fig. 2f).
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The NCI-MD data were derived from patients enrolled in the ongoing NCI-MD CaseControl Study [https://clinicaltrials.gov/ct2/show/NCT00339859]. The fastq ﬁles, race
and processed data of the data set generated during the current study have been uploaded
to GEO repository under accession number GSE174330. The processed data are available
in the Supplementary Data ﬁle. PolyA database in human tissues published by Derti
et al.29, is available from GEO repository under accession number GSE30198. PolyA
database in human tissues published by Gruber et al.69, is available from NCBI Read
Archive under accession number SRP065825. The TGCA data used in this study can be
accessed at http://tc3a.org. The RIP-Seq data used in this study are available from GEO
repository under accession number GSE35585. The CTPAC data portal is accessible at
https://cptac-data-portal.georgetown.edu/datasets. The GDAC data can be accessed at
https://portal.gdc.cancer.gov/. Raw data for all the remaining ﬁgures are provided in the
Supplementary Data ﬁle. Source data are provided with this paper.

Code availability
Codes generated in this study are provided as a Supplementary Software ﬁle.
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